Regenerx Biopharmaceuticals Inc financial data

Location
15245 Shady Grove Road, Suite 470, Rockville, MD
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 50.7 % -83.5%
Debt-to-equity -114 % +33.7%
Return On Equity 51.2 % -35.9%
Return On Assets -358 % -224%
Operating Margin -1.78K % +0.72%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 144M shares 0%
Common Stock, Shares, Outstanding 144M shares 0%
Entity Public Float 16M USD 0%
Common Stock, Value, Issued 144K USD 0%
Weighted Average Number of Shares Outstanding, Basic 144M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 144M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 76.8K USD 0%
General and Administrative Expense 1.44M USD -0.26%
Operating Income (Loss) -1.36M USD +0.72%
Nonoperating Income (Expense) -326K USD -20.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.69M USD -2.83%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.69M USD -2.83%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102K USD -89%
Assets, Current 123K USD -86.9%
Operating Lease, Right-of-Use Asset 57.8K USD +257%
Other Assets, Noncurrent 5.75K USD 0%
Assets 187K USD -80.6%
Accounts Payable, Current 38.7K USD +22.1%
Accrued Liabilities, Current 469K USD +68.6%
Contract with Customer, Liability, Current 76.8K USD 0%
Liabilities, Current 1.8M USD +347%
Contract with Customer, Liability, Noncurrent 1.85M USD -3.98%
Operating Lease, Liability, Noncurrent 17.7K USD
Liabilities 3.93M USD +11.5%
Retained Earnings (Accumulated Deficit) -113M USD -1.52%
Stockholders' Equity Attributable to Parent -3.74M USD -45.9%
Liabilities and Equity 187K USD -80.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -189K USD +38.2%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 144M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -189K USD +38.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 102K USD -89%
Operating Lease, Liability 63.7K USD +291%
Lessee, Operating Lease, Liability, to be Paid 73.1K USD +331%
Operating Lease, Liability, Current 46K USD +182%
Lessee, Operating Lease, Liability, to be Paid, Year Two 32.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 40.9K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.45K USD +1281%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Share-based Payment Arrangement, Expense 511K USD +20.5%
Interest Expense 326K USD +0.24%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%